BACKGROUND: Limited progress has been made in the management of cardiogenic shock (CS). Morbidity and mortality of refractory CS remain high. The effects of mechanical circulatory support (MCS) are promising, although many aspects are elusive. We evaluated efficacy and safety of early combined MCS (Impella microaxial pump + venoarterial extracorporeal membrane oxygenation [VA-ECMO]) in refractory CS and aimed to determine factors for decision-making in combined MCS. METHODS AND RESULTS: We analyzed 69 consecutive patients with refractory CS from our registry requiring combined MCS. In 12 cases, therapy was actively withdrawn according to patient's will. Patients were severely sick (Survival After Venoarterial ECMO score mean±SD, -8.9±4.4) predicting 30% in-hospital survival; ventilation 94%, dialysis 56%. Impella pumps and VA-ECMO were combined early (duration of combined MCS: median 94 hours; interquartile range, 49-150 hours). Early MCS escalation stabilized patients rapidly, reducing number and doses of catecholamines (P<0.05 versus baseline) while hemodynamics improved. Reflecting an improved microcirculation, lactate levels normalized within 24 hours (P<0.05 versus baseline). Despite refractory CS and disease severity, survival was favorable (on MCS 61%, 30 days 49%, 6 months 40%). In multivariate Cox-regression, duration of shock-to-first device (hours, hazard ratio, 1.05 [95% CI, 1.01-1.08]; P=0.007) and lactate levels after 12 hours of MCS (hazard ratio, 1.28 [95% CI, 1.09-1.51]; P=0.002) independently predicted survival. Additional right ventricular failure predisposed to futility (hazard ratio, 8.48 [95% CI, 1.85-38.91]; P=0.006). CONCLUSIONS: The early and consequent combination of MCS by Impella microaxial pumps and VA-ECMO enables stabilization and may rescue high-risk patients with refractory CS at low overall risk. Independent predictors of survival may guide prognostication, decision-making, and allocation of medical resources.
BACKGROUND: Limited progress has been made in the management of cardiogenic shock (CS). Morbidity and mortality of refractory CS remain high. The effects of mechanical circulatory support (MCS) are promising, although many aspects are elusive. We evaluated efficacy and safety of early combined MCS (Impella microaxial pump + venoarterial extracorporeal membrane oxygenation [VA-ECMO]) in refractory CS and aimed to determine factors for decision-making in combined MCS. METHODS AND RESULTS: We analyzed 69 consecutive patients with refractory CS from our registry requiring combined MCS. In 12 cases, therapy was actively withdrawn according to patient's will. Patients were severely sick (Survival After Venoarterial ECMO score mean±SD, -8.9±4.4) predicting 30% in-hospital survival; ventilation 94%, dialysis 56%. Impella pumps and VA-ECMO were combined early (duration of combined MCS: median 94 hours; interquartile range, 49-150 hours). Early MCS escalation stabilized patients rapidly, reducing number and doses of catecholamines (P<0.05 versus baseline) while hemodynamics improved. Reflecting an improved microcirculation, lactate levels normalized within 24 hours (P<0.05 versus baseline). Despite refractory CS and disease severity, survival was favorable (on MCS 61%, 30 days 49%, 6 months 40%). In multivariate Cox-regression, duration of shock-to-first device (hours, hazard ratio, 1.05 [95% CI, 1.01-1.08]; P=0.007) and lactate levels after 12 hours of MCS (hazard ratio, 1.28 [95% CI, 1.09-1.51]; P=0.002) independently predicted survival. Additional right ventricular failure predisposed to futility (hazard ratio, 8.48 [95% CI, 1.85-38.91]; P=0.006). CONCLUSIONS: The early and consequent combination of MCS by Impella microaxial pumps and VA-ECMO enables stabilization and may rescue high-risk patients with refractory CS at low overall risk. Independent predictors of survival may guide prognostication, decision-making, and allocation of medical resources.
Authors: Enzo Lüsebrink; Leonhard Binzenhöfer; Antonia Kellnar; Christoph Müller; Clemens Scherer; Benedikt Schrage; Dominik Joskowiak; Tobias Petzold; Daniel Braun; Stefan Brunner; Sven Peterss; Jörg Hausleiter; Sebastian Zimmer; Frank Born; Dirk Westermann; Holger Thiele; Andreas Schäfer; Christian Hagl; Steffen Massberg; Martin Orban Journal: Clin Res Cardiol Date: 2022-08-20 Impact factor: 6.138
Authors: Benedikt Schrage; Peter Moritz Becher; Alexander Bernhardt; Hiram Bezerra; Stefan Blankenberg; Stefan Brunner; Pascal Colson; Gaston Cudemus Deseda; Salim Dabboura; Dennis Eckner; Matthias Eden; Ingo Eitel; Derk Frank; Norbert Frey; Masaki Funamoto; Alina Goßling; Tobias Graf; Christian Hagl; Paulus Kirchhof; Danny Kupka; Ulf Landmesser; Jerry Lipinski; Mathew Lopes; Nicolas Majunke; Octavian Maniuc; Daniel McGrath; Sven Möbius-Winkler; David A Morrow; Marc Mourad; Curt Noel; Peter Nordbeck; Martin Orban; Federico Pappalardo; Sandeep M Patel; Matthias Pauschinger; Vittorio Pazzanese; Hermann Reichenspurner; Marcus Sandri; P Christian Schulze; Robert H G Schwinger; Jan-Malte Sinning; Adem Aksoy; Carsten Skurk; Lukasz Szczanowicz; Holger Thiele; Franziska Tietz; Anubodh Varshney; Lukas Wechsler; Dirk Westermann Journal: Circulation Date: 2020-10-09 Impact factor: 29.690
Authors: Brian Y Chang; Christian Moyer; Ahmad El Katerji; Steven P Keller; Elazer R Edelman Journal: IEEE Trans Biomed Eng Date: 2021-02-18 Impact factor: 4.538
Authors: Vera Garcheva; Muharrem Akin; John Adel; Carolina Sanchez Martinez; Johann Bauersachs; Andreas Schäfer Journal: PLoS One Date: 2021-05-04 Impact factor: 3.240
Authors: Jan-Thorben Sieweke; Muharrem Akin; Sebastian Stetskamp; Christian Riehle; Danny Jonigk; Ulrike Flierl; Tobias J Pfeffer; Valentin Hirsch; Jochen Dutzmann; Marius M Hoeper; Christian Kühn; Johann Bauersachs; Andreas Schäfer Journal: Eur Respir J Date: 2020-09-03 Impact factor: 16.671